Inactive

Solicitation: SPE2DP-23-R-0002 Item: ANTIDOTE TREATMENT, NERVE AGENT, Automatic, Dual-Chamber, Pralidoxime Chloride Injection, 300 mg per mL, 2 mL, and Atropine Injection, 2.99 mg per mL, 0.7 mL NSN: ... Solicitation: SPE2DP-23-R-0002 Item: ANTIDOTE TREATMENT, NERVE AGENT, Automatic, Dual-Chamber, Pralidoxime Chloride Injection, 300 mg per mL, 2 mL, and Atropine Injection, 2.99 mg per mL, 0.7 mL NSN: 6505-01-362-7427 Description: The Defense Logistics Agency Troop Support has a requirement for the supply of Antidote Treatment Nerve Agent Auto-Injector (ATNAA). ATNAA shall be made in accordance with MPID Number 6 dated May 2, 2019. The Solicitation will be issued under authority 10 U.S.C. 2304(c)(1). The Government does not intend to use Part 12 for this acquisition – per FAR 10.002(d)(2). The proposed contract will be a firm-fixed price, indefinite delivery, indefinite quantity type contract. The contract will consist of a base year and four (4) one-year options. The quantities for the base year and each option year are a minimum of 225,000 each and a maximum of 1,000,000 each. Inspection/Acceptance at Destination FOB Destination Delivery Destination: Susquehanna, PA Production Lead Time is 164 days after issuance date of the delivery order (DD1155). All responsible sources may submit a proposal and shall be considered by the Agency. The successful contractor shall have FDA approval to sell ATNAA before award decision. **************************************************************************** IMPORTANT NOTICES Availability of solicitations, FAR 5.102(d) applies, as our office no longer issues solicitations or amendments in paper form. Offeror should register to receive notification of this solicitation or solicitation amendments. The solicitation will be posted on the DLA Internet Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil/. Detailed system requirements and instructions for registration can be found on the DLA DIBBS Home Page accessed on https://www.dibbs.bsm.dla.mil/. Once the solicitation is posted, it will be available for viewing on DIBBS. From the DIBBS homepage, select "Solicitations" from the top bar to search for the solicitation. DIBBS Help can be accessed from the DIBBS homepage. Interested parties are further advised to set up automated notifications of solicitation changes through this website. Solicitation SPE2DP-23-R-0002 is expected to be issued on or around May 2024. ******************************************************************************

Inactive

The Defense Logistics Agency Troop Support is seeking sources capable of providing the Antidote Treatment Nerve Agent Auto-Injector (ATNAA). DLA Troop Support is contemplating awarding a one-year base... The Defense Logistics Agency Troop Support is seeking sources capable of providing the Antidote Treatment Nerve Agent Auto-Injector (ATNAA). DLA Troop Support is contemplating awarding a one-year base and two one-year option, indefinite quantity contract for ATNAA. The quantities to be ordered are estimated at 225,000 units minimum and 1,000,000 units maximum per contract year. However, the quantity may increase or decrease as the Services requirements change. The ATNAA shall be licensed by the Food and Drug Administration (FDA). Each auto-injector shall deliver 2.1 mg of atropine and 600mg of pralidoxime chloride in separate chambers, and be suitable for intramuscular administration. Must have FDA approval to sell the ATNAA before award of the contract. If your firm currently manufactures or distributes the ATNAA, please provide information with respect to the following: a) Place of manufacture b) Estimated annual capacity c) FDA registration d) Product name and description including description of any special features e) Current unit sale price f) Estimated inventory level and storage requirements *** NEW PRODUCTS UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the ATNAA or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Your response to this RFI may be submitted electronically in pdf format and emailed to danielle.delaney@dla.mil. Responses must be submitted by July 5, 2023.